Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 123-132 , April 2002

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

  • Lowell B. Anthony

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA
    • Corresponding Author InformationAddress reprint requests to Lowell B. Anthony, MD, Department of Medicine, Division of Hematology and Oncology, Louisiana State University Health Sciences Center, 1542 Tulane Ave, New Orleans, LA 70112.
    • ,
  • Eugene A. Woltering

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA
    • ,
  • Gregory D. Espenan

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA
    • ,
  • Michele D. Cronin

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA
    • ,
  • Tom J. Maloney

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA
    • ,
  • Kevin E. McCarthy

      Affiliations

    • Louisiana State University Medical Center, Department of Medicine, Surgery, USA
    • Louisiana State University Medical Center, Department of Radiology, USA
    • Louisiana State University Health Sciences Center (LSUHSC), Stanley S. Scott Cancer Center, New Orleans, LA, USA
    • Iso-tex Diagnostics, Inc., Friendswood, TX, USA

References 

  1. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 1968;83:783–790
  2. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77–79
  3. Schally AV. Oncological applications of somatostatin analogues [published erratum appears in Cancer Res 49:1618, 1989]. Cancer Res. 1988;48:6977–6985
  4. Raynor K, Murphy WA, Coy DH, et al. Cloned somatostatin receptors: Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol. 1993;43:838–844
  5. Raynor K, O'Carroll AM, Kong H, et al. Characterization of cloned somatostatin receptors SSTR4 and SSTR5. Mol Pharmacol. 1993;44:385–392
  6. Patel PC, Barrie R, Hill N, et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surg. 1994;116:1148–1152
  7. Pan MG, Florio T, Stork PJ. G Protein activation of a hormone-stimulated phosphatase in human tumor cells. Science. 1992;256:1215–1217
  8. Zink A, Scherubl H, Kliemann D, et al. Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: Involvement of pertussis toxin-sensitive G-proteins. Mol Cell Endocrinol. 1992;86:213–219
  9. Hsu DW, Hooi SC, Hedley-Whyte ET, et al. Coexpression of galanin and adrenocorticotropic hormone in human pituitary and pituitary adenomas. Am J Pathol. 1991;138:897–909
  10. Hsu WH, Xiang HD, Rajan AS, et al. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell. J Biol Chem. 1991;266:837–843
  11. Reubi JC, Lamberts SW, Maurer R. Somatostatin receptors in normal and tumoral tissue. Horm Res. 1988;29:65–69
  12. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–244
  13. Lamberts SW, Bakker WH, Reubi JC, et al. Somatostatin-receptor imaging in the localization of endocrine tumors [see comments]. N Engl J Med. 1990;323:1246–1249
  14. [Review] Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  15. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction?. Int J Cancer. 1994;56:681–688
  16. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metab Clin Exp. 1996;45(suppl 1):39–41
  17. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res. 1991;50:245–251
  18. [Review] Woltering EA, Watson JC, Alperin-Lea RC, et al. Somatostatin analogs: Angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs. 1997;15:77–86
  19. Danesi R, Benelli U, Del Bianchi S, et al. Octreotide inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea (Meeting abstract). In: Proc Annu Meet Am Assoc Cancer Res. 34:1993;p. A2109
  20. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metab Clin Exp. 1996;45(suppl 1):49–50
  21. Danesi R, Agen C, Benelli U, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res. 1997;3:265–272
  22. Sahu SK, Kortylewicz ZP, Baranowska-Kortylewicz J, et al. Strand breaks after the decay of iodine-125 in proximity to plasmid pBR322 DNA. Radiat Res. 1997;147:401–408
  23. Andersson P, Forssell-Aronsson E, Johanson V, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med. 1996;37:2002–2006
  24. Hofland LJ, van Koetsveld PM, Waaijers M, et al. Internalisation of isotope-coupled somatostatin analogues. Digestion. 1996;57(suppl 1):2–6
  25. Janson ET, Westlin JE, Ohrvall U, et al. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors [see comments]. J Nucl Med. 2000;41:1514–1518
  26. Morel G. Internalization and nuclear localization of peptide hormones. Biochem Pharmacol. 1994;47:63–76
  27. Lukinius A, Ohrvall U, Westlin JE, et al. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. Acta Oncol. 1999;38:383–387
  28. Hornick CA, Anthony CT, Hughey S, et al. Progressive nuclear translocation of somatostatin analogs. J Nucl Med. 2000;41:1256–1263
  29. Meyers MO, Anthony CT, Coy DH, et al. Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity. J Surg Res. 1998;76:154–158
  30. Behr TM, Sgouros G, Vougiokas V, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies. Evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer. 1998;76:738–748
  31. Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: Comparison of Auger electron emitters with beta-particle emitters. J Nucl Med. 2000;41:2089–2097
  32. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue [111In- DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506
  33. Meyers MO, Anthony LB, McCarthy KE, et al. High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. South Med J. 2000;93:809–811
  34. McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Am. 1998;4:94–102
  35. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113–117
  36. Moertel CG. Progress and hope in the treatment of gastrointestinal cancer. In: Fortner JG, Rhoads JE editor. Accomplishments in Cancer Research 1987. Philadelphia: J.B. Lippincott; 1988;p. 295–317
  37. [Review] Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993;32:197–201
  38. Zuetenhorst H, Taal BG, Boot H, et al. Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): Pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999;11:1157–1164
  39. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  40. Fjalling M, Andersson P, Forssell-Aronsson E, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phel-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519–1521
  41. Tiensuu Janson E, Eriksson B, Oberg K, et al. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors—evaluation of therapeutic and toxic effects. Acta Oncol. 1999;38:373–377

* Supported in part by NIH-GCRC-RR05096-07 and the LSUHSC Foundation.

PII: S0001-2998(02)80030-7

doi: 10.1053/snuc.2002.31769

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 123-132 , April 2002

Article Tools